Drug intelligence / Profile preview

FID 114657

Development stage: Unknown
Lead developer: Alcon
Administration: Ophthalmic

Overview

FID 114657 is an **ocular emulsion** developed for the relief of dry eye symptoms, including in patients with Sjögren’s syndrome. It is referred to as an "artificial tear emulsion," designed to improve the ocular surface and enhance tear film stability. Clinical studies have measured endpoints such as corneal staining, meibomian gland function, tear breakup time, and dosing frequency in patients with dry eye disease, showing statistically significant improvements in relevant clinical parameters. The active ingredients and detailed mechanism of action (e.g., specific lipid or emollient composition) have not been disclosed in publicly available sources, and the product appears to act through ocular surface lubrication and tear film supplementation[1][3][5][7].

Brand names: ORB Preserved Ocular Emulsion
Other names: ORB Preserved Ocular Emulsion

Beyond the preview

Go deeper on FID 114657.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FID 114657.

Explore the full profile